{"id":"NCT01509677","sponsor":"AstraZeneca","briefTitle":"Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease","officialTitle":"A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02-01","primaryCompletion":"2016-02-01","completion":"2016-02-01","firstPosted":"2012-01-13","resultsPosted":"2019-11-29","lastUpdate":"2019-11-29"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COPD","Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Roflumilast","otherNames":["Daxas"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo to Roflumilast"]}],"arms":[{"label":"Roflumilast","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the Biopsy trial is to investigate the effect of roflumilast 500 Âµg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum. Also data on safety status will be obtained.\n\nPatients to be included required to have moderate to severe COPD associated with chronic bronchitis. The total duration of this randomized, multicentre, phase III trial is 24 weeks maximum.","primaryOutcome":{"measure":"Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.","timeFrame":"16 weeks","effectByArm":[{"arm":"R500","deltaMin":442.4,"sd":312.74},{"arm":"Placebo","deltaMin":427.1,"sd":261.42}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":20,"countries":["Denmark","Germany","Poland","Sweden","United Kingdom"]},"refs":{"pmids":["30224319"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4560&filename=RO-2455-402-RD_ROBERT_Updated_Protocol_v6.0_(Amendment_12)_-_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":79},"commonTop":["Nasopharyngitis","Cough","COPD","Diarrhoea","Insomnia"]}}